フォロー
Jochen Sven Utikal, MD
Jochen Sven Utikal, MD
Professor for Dermatooncology, German Cancer Research Center and University Medical Center Mannheim
確認したメール アドレス: dkfz.de
タイトル
引用先
引用先
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ...
Science 350 (6257), 207-211, 2015
26752015
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
25622012
Induced pluripotent stem cells generated without viral integration
M Stadtfeld, M Nagaya, J Utikal, G Weir, K Hochedlinger
Science 322 (5903), 945-949, 2008
22912008
Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution
N Maherali, R Sridharan, W Xie, J Utikal, S Eminli, K Arnold, M Stadtfeld, ...
Cell stem cell 1 (1), 55-70, 2007
22412007
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
U Sahin, E Derhovanessian, M Miller, BP Kloke, P Simon, M Löwer, ...
Nature 547 (7662), 222-226, 2017
21532017
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
19562014
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
15192015
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells
J Utikal, JM Polo, M Stadtfeld, N Maherali, W Kulalert, RM Walsh, A Khalil, ...
Nature 460 (7259), 1145-1148, 2009
10572009
A high-efficiency system for the generation and study of human induced pluripotent stem cells
N Maherali, T Ahfeldt, A Rigamonti, J Utikal, C Cowan, K Hochedlinger
Cell stem cell 3 (3), 340-345, 2008
7322008
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ...
Annals of Oncology 28 (7), 1631-1639, 2017
7102017
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ...
European journal of cancer 60, 190-209, 2016
6672016
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky, M Vormehr, ...
Nature 585 (7823), 107-112, 2020
6162020
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
C Groth, X Hu, R Weber, V Fleming, P Altevogt, J Utikal, V Umansky
British journal of cancer 120 (1), 16-25, 2019
6122019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, ...
Nature medicine 25 (12), 1916-1927, 2019
6062019
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ...
European journal of cancer 60, 210-225, 2016
5722016
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression
S Eminli, J Utikal, K Arnold, R Jaenisch, K Hochedlinger
Stem cells 26 (10), 2467-2474, 2008
5042008
Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors
R Weber, V Fleming, X Hu, V Nagibin, C Groth, P Altevogt, V Umansky
Frontiers in immunology 9, 380053, 2018
4762018
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task
TJ Brinker, A Hekler, AH Enk, J Klode, A Hauschild, C Berking, B Schilling, ...
European Journal of Cancer 113, 47-54, 2019
4292019
Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression
V Fleming, X Hu, R Weber, V Nagibin, C Groth, P Altevogt, J Utikal, ...
Frontiers in immunology 9, 398, 2018
4292018
Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells
J Utikal, N Maherali, W Kulalert, K Hochedlinger
Journal of cell science 122 (19), 3502-3510, 2009
4162009
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20